Mabwell (Shanghai) Bioscience Co., Ltd. Announces 2026 Third Extraordinary General Meeting: Key Resolutions and Shareholder Implications
Key Highlights for Investors
- Date of EGM: June 18, 2026, 3:00 p.m. at Conference Room 103, Building 3, Chuangxiang Park, No. 576, Libing Road, Pudong New Area, Shanghai, China.
- Purpose: To consider and vote on a series of ordinary resolutions that could impact the future direction and governance of the company.
Key Resolutions to be Voted On
- Remuneration Management System: Shareholders will vote to approve a new remuneration management system for Directors and senior management. This system will determine how top executives are compensated, which could have an impact on the company’s ability to attract and retain talent.
- 2026 Remuneration Plan for Directors: A specific remuneration plan for the year 2026 is up for approval, directly affecting director compensation and potentially influencing governance and strategic direction.
- Appointment of Auditor: The meeting will consider the appointment of Ernst & Young as the auditor for H Shares for the year 2026. Auditor selection is crucial for financial transparency and investor confidence.
- General Mandate to Issue Additional H Shares: Shareholders are asked to grant a general mandate that allows the company to issue additional H Shares. If approved, this mandate could lead to share dilution, but also provides the company with flexibility to raise capital for expansion, acquisitions, or other strategic initiatives.
- Election of Executive Directors: The following candidates are proposed for election as executive directors:
- Mr. Tang Chunshan
- Dr. Liu Datao
- Dr. Wu Hai
- Mr. Hua Jun
- Election of Independent Non-Executive Directors: The following candidates are proposed as independent non-executive directors:
- Mr. Qin Zhengyu
- Mr. Zhou Rui
- Ms. Li Fan
- Ms. Wang Fang
Important Information for Shareholders
- Eligibility to Attend and Vote: Only shareholders whose names appear on the register of members on June 18, 2026, are eligible to attend and vote. The register will be closed from June 15 to June 18, 2026. All transfers must be lodged by June 12, 2026, 4:30 p.m.
- Proxy Voting: Shareholders may appoint one or more proxies to attend and vote on their behalf. All proxy documents must be delivered to Tricor Investor Services Limited by 3:00 p.m., June 17, 2026.
- Voting by Poll: All resolutions will be voted on by poll, in line with Hong Kong Listing Rules. Results will be published on the company and HKSE websites.
- Meeting Logistics: The meeting will be conducted in Mandarin and is expected to last no more than half a day. No gifts or marketable securities will be distributed, and shareholders must bear their own travel and accommodation expenses.
- Director Line-up (as of the date of notice):
- Executive Directors: Mr. Tang Chunshan, Dr. Liu Datao (Chairman), Dr. Wu Hai, Mr. Hu Huiguo, Dr. Gui Xun
- Non-Executive Director: Mr. Wu Yufeng
- Independent Non-Executive Directors: Mr. Qin Zhengyu, Dr. Xu Qing, Dr. Zhao Qian, Ms. Wang Fang
Potential Share Price Sensitivities
- Share Issuance Mandate: Granting the mandate to issue additional H Shares could lead to near-term share price volatility due to potential dilution, but also signals the company’s intention to pursue growth or strategic initiatives requiring capital.
- Director and Management Compensation: Approval of new remuneration systems and plans may impact investor perceptions of governance and cost control, affecting confidence in management’s alignment with shareholder interests.
- Board Composition Changes: Election of new executive and independent non-executive directors could alter company strategy, governance style, or risk appetite, creating uncertainty or opportunity depending on market perception of the new directors’ reputations and expertise.
- Auditor Appointment: Retaining a top-tier auditor like Ernst & Young helps support transparency and may boost investor trust.
Instructions and Contact
- For questions regarding the EGM, shareholders may contact Tricor Investor Services Limited at (852) 2980 1333 during business hours.
- All times and dates referenced are Hong Kong time.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisers before making any investment decisions. The company and the author accept no liability for any losses arising from reliance on this information.
萬泰生物（上海）生物科技有限公司2026年第三次臨時股東大會通告詳情
投資者重點摘要
- 會議日期：2026年6月18日 下午3時，地點為中國上海市浦東新區立斌路576號創想園3號樓103會議室。
- 會議目的：審議及表決多項可能影響公司未來發展及治理的普通決議案。
股東大會主要決議案詳情
- 董事及高管薪酬管理制度：投票通過新薪酬管理制度，該制度將影響管理層激勵與吸引力，甚至影響公司戰略執行力。
- 2026年董事薪酬方案：審批2026年度董事薪酬，將直接影響公司治理層的激勵政策。
- 任命審計師：決議聘任安永會計師事務所為2026年度H股審計師，這對公司審計透明度及公信力具重要意義。
- 發行額外H股的一般授權：如獲批，董事會可靈活發行H股，雖可能帶來攤薄風險，但也為公司籌資或擴展業務提供空間。
- 選舉執行董事：
- 唐春山先生
- 劉大濤博士
- 吳海博士
- 華軍先生
- 選舉獨立非執行董事：
- 秦正宇先生
- 周銳先生
- 李凡女士
- 王芳女士
股東必須注意的重要事項
- 出席及投票資格：2026年6月18日名冊上的股東方有資格出席及投票。股份登記於6月15日至18日期間暫停，所有過戶需於6月12日下午4:30前辦理。
- 委任代理人：股東可委任一名或多名代理人出席及投票，所有委託文件須於6月17日下午3時前遞交至卓佳證券登記有限公司。
- 投票方式：根據香港上市規則，所有決議案將以投票方式處理，結果將於香港聯交所及公司網站公布。
- 會議安排：會議以普通話進行，預計不超過半天。現場不設禮品或證券派發，出席者須自理交通及住宿。
- 現任董事會成員：
- 執行董事：唐春山先生、劉大濤博士（董事長）、吳海博士、胡惠國先生、桂勛博士
- 非執行董事：吳宇峰先生
- 獨立非執行董事：秦正宇先生、徐清博士、趙倩博士、王芳女士
可能影響股價的因素
- 增發股份授權：如獲批准，未來增發H股有機會令股價短期波動，既有攤薄風險，亦可能預示公司有資本運作或拓展計劃。
- 薪酬政策調整：新薪酬方案或影響市場對公司治理及成本控制信心，進而影響管理層與股東利益一致性。
- 董事會組成變動：新董事委任或影響公司策略、治理風格及風險偏好，市場對新班子專業背景的評價或帶來不確定性與機會。
- 審計師續聘：延續安永等頂級審計師有助增強投資者信任。
查詢及聯絡方式
- 如有疑問可於辦公時間致電(852) 2980 1333聯絡卓佳證券登記有限公司。
- 所有時間日期均為香港時間。
免責聲明：本文僅供參考，非投資建議。投資者應自行做足功課及諮詢專業顧問。公司及作者不對因依賴本文而導致的任何損失承擔責任。
